Table 1.
Prevalence of ESR1m in published studies including more than 100 patients.
| Reference | Number of patients (n) | ESR1m prevalence (%) | Methods |
|---|---|---|---|
| Fribbens et al. (PALOMA 3 cohort) (23) | 360 | 25 | Plasma circulating tumor DNA (ctDNA) ddPCR |
| Fribbens et al. (SOFEA cohort) (23) | 161 | 39 | Plasma ctDNA ddPCR |
| Chandarlapaty et al. (BOLERO-2 cohort) (21) | 541 | 29 | Plasma ctDNA ddPCR |
| Clatot (22) | 144 | 31 | Plasma ctDNA ddPCR |
| Spoerke (FERGI cohort) (25) | 153 | 37 | Plasma ctDNA ddPCR |
| Schiavon (24) | 171 | 11 | Plasma ctDNA ddPCR |
| Jeselson (2) | 187 | 21 | Metastatic tumor biopsies next-generation sequencing (NGS) |
| Niu (26) | 222 | 12 | Metastatic tumor biopsies NGS |